期刊文献+

替雷利珠单抗致Stevens-Johnson综合征的病例分析及药学监护

Stevens-Johnson Syndrome Caused by Terelitizumab and Related Pharmaceutical Care
下载PDF
导出
摘要 目的探讨替雷利珠单抗致Stevens-Johnson综合征不良反应的治疗方法,为临床预防及治疗提供参考。方法临床药师对1例肺腺癌患者使用化疗联合替雷利珠单抗后出现Stevens-Johnson综合征的病例进行分析和讨论,协助医师制定治疗措施。结果患者经糖皮质激素及免疫球蛋白治疗后,皮肤症状缓解。结论警示临床人员充分认识该药所导致的严重不良反应,重视和早期识别免疫相关不良反应,确保安全使用管理,提高治疗效果,为患者带来更多的临床获益。 Objective To explore the therapeutic strategies for terelizumab-induced adverse reactions to Stevens-Johnson syndrome,and to provide reference for clinical prevention and treatment of this disease.Methods Clinical pharmacists analyzed and discussed the case of Stevens-Johnson syndrome in a patient with lung adenocarcinoma treated with chemotherapy combined with tirelizumab before they assisted the physicians in formulating treatment plans.Results After corticosteroid and immunoglobulin therapy,the skin symptoms were mitigated.Conclusion Clinical pharmacists can collaborate with physicians to provide pharmacological monitoring and pharmacy services for immune-related adverse events.
作者 孙丽丹 嵇书霞 张丹 訾晨晨 王慧 鲍蕾蕾 SUN Li-dan;JI Shu-xia;ZHANG Dan;ZI Chen-chen;WANG Hui;BAO Lei-lei(Third Affiliated Hospital of Naval Military Medical University,Shanghai 200438,China;First Affiliated Hospital of Naval Military Medical University,Shanghai 200433,China;Luodian Hospital,Baoshan District,Shanghai 201908,China)
出处 《解放军药学学报》 CAS 2022年第3期252-254,共3页 Pharmaceutical Journal of Chinese People's Liberation Army
关键词 替雷利珠单抗 药物不良反应 STEVENS-JOHNSON综合征 药学监护 terelizumab drug adverse reactions Stevens-Johnson syndrome pharmaceutical care
  • 相关文献

参考文献9

二级参考文献42

  • 1滕小玉,管忠震,姚志文,刘冬耕,周宁宁,罗汉钰,Michael Hawkins,Patrick Soon-Shiong.晚期实体癌患者对不含聚氧乙烯蓖麻油注射用紫杉醇白蛋白纳米粒悬浮液的临床耐受性研究[J].癌症,2004,23(z1):1431-1436. 被引量:39
  • 2[1]Taxol(R) (paclitaxel) Injection [package insert]. Princeton, New Jersey: Bristol-Myers Squibb Co; March 2003
  • 3[2]Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor EL and its derivatives: Oxethylated oleic acid is the most effective constituent [ J]. Agents Actions, 1977, 7 ( 1 ): 63 -67.
  • 4[3]Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation [J]. Eur J Cancer, 2001, 37(13): 1590 - 1598.
  • 5[4]Rowinsky EK, Donehower RC. Paclitaxel (taxol) [J]. N Engl J Med, 1995, 332(15): 1004 - 1014.
  • 6[5]Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to Paclitaxel: an in vitro study [J]. J Natl Cancer Inst, 1998, 90(4):300 - 305.
  • 7[6]ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy [J] .Clin Pharmacokinet, 2003, 42 (7): 665 - 685.
  • 8[7]van Zuylen L, Karlsson MO, Verweij J, et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles [J]. Cancer Chemother Pharmacol, 2001, 47(4): 309 - 318.
  • 9[8]Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood:clinical pharmacokinetic implications [J] . Cancer Res, 1999, 59(7): 1454 - 1457.
  • 10[9]Ibrahim NK, Desai N, Legha S, et al. Phase Ⅰ and pharmacokinetic study of ABI-007, a Cremophor-free proteinstabilized. nanoparticle formulation of paclitaxel [J]. Clin Cancer Res, 2002, 8(5): 1038 - 1044.

共引文献360

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部